Ipsen Aktie

117,40 EUR -5,30 EUR -4,32 %

22.01.2025

STU

116,60 EUR -3,80 EUR -3,16 %

22.01.2025

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.9,91 Mrd. EUR

KGV13,85Div. Rendite1,11%

WKNA0ESMG

ISINFR0010259150

SymbolIPSEF

Ipsen Aktien News

Sortieren:Datum Meistgelesen

03.06.24GlobeNewswireIpsen initiates a share buy-back program to cover its free employee share-allocation plan

30.05.24GlobeNewswireIpsen announces the launch of an employee shareholding plan

28.05.24GlobeNewswireAnnual General Meeting of Ipsen S.A. held on 28 May 2024

28.05.24GlobeNewswireDescription of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

07.05.24GlobeNewswireIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

06.05.24GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

02.05.24GlobeNewswireIpsen appoints Keira Driansky as EVP, President of North America

24.04.24GlobeNewswireIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

22.04.24GlobeNewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

22.04.24PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

17.04.24GlobeNewswireIpsen publishes its 2023 Universal Registration Document

08.04.24GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

02.04.24PR NewswireMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen

02.04.24GlobeNewswireIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

07.03.24GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

15.02.24GlobeNewswireIpsen S.A. publishes its 2023 Consolidated Financial Statements

13.02.24GlobeNewswireIpsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

08.02.24GlobeNewswireBuilding on solid FY 2023 results, Ipsen anticipates four launches in 2024

06.02.24GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

22.01.24GlobeNewswireLatest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

08.01.24GlobeNewswireIpsen – Half year statement – 2023 12 31

05.01.24GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

07.12.23GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

07.12.23GlobeNewswireCapital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

07.12.23GlobeNewswireIpsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

14.11.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023

13.11.23GlobeNewswireResults from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

13.11.23PR NewswireIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

07.11.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023

06.11.23GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

31.10.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2023

26.10.23GlobeNewswireIpsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

24.10.23GlobeNewswireIPSEN - Buy-back program - Art 5 of MAR - Week 42 - 2023

23.10.23GlobeNewswireIpsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome

17.10.23GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2023

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.